دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The complex link among heart failure, atrial fibrillation, and lung diseases, and an update on cardiac transplantation
Filippo Crea
doi : 10.1093/eurheartj/ehac297
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2165–2169
Unmet needs in the management of arrhythmias among heart failure patients in Africa
Reuben Kato Mutagaywa, Ashley Chin, Kamilu Karaye, Aime Bonny
doi : 10.1093/eurheartj/ehac040
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2170–2172
European Reference Network for rare, low prevalence, or complex diseases of the heart (ERN GUARD-Heart): 5 year anniversary
Ahmad S Amin, Ruth Biller, Philippe Charron, Arthur A M Wilde
doi : 10.1093/eurheartj/ehac117
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2173–2176
Renal denervation therapy for hypertension: all that glitters is not gold
C Venkata S Ram
doi : 10.1093/eurheartj/ehac065
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2177–2178
The PACMAN-AMI trial: game over for the “vulnerable plaque�?
Rocco Vergallo, Carlo Patrono
doi : 10.1093/eurheartj/ehac222
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2179–2180
The European Heart Journal: fulfilling the mission
Filippo Crea, Lina Badimon, Colin Berry, Raffaele De Caterina, Perry M Elliott, Robert Hatala, Peter Libby, Cecilia Linde, Anne Tybjaerg-Hansen
doi : 10.1093/eurheartj/ehac171
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2181–2184
September 2020, the new Editors of the European Heart Journal (EHJ) wrote the following in their inaugural editorial: “The fundamental mission of the Journal remains the reduction of the global burden of cardiovascular disease.
Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
Suleman Aktaa, Gorav Batra, John G F Cleland, Andrew Coats, Lars H Lund, Theresa McDonagh, Giuseppe Rosano, Petar Seferovic, Peter Vasko, Lars Wallentin, Aldo P Maggioni, Barbara Casadei, Chris P Gale, In Collaboration with the Heart Failure Association of the European Society of Cardiology
doi : 10.1093/eurheartj/ehac151
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2185–2195
Standardized data definitions are essential for assessing the quality of care and patient outcomes in observational studies and randomized controlled trials.
Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study
Christina M Eckhardt, Pallavi P Balte, Robert Graham Barr, Alain G Bertoni, Surya P Bhatt, Michael Cuttica, Patricia A Cassano, Paolo Chaves, David Couper, David R Jacobs, Ravi Kalhan, Richard Kronmal, Leslie Lange, Laura Loehr, Stephanie J London, George T O’Connor, Wayne Rosamond, Jason Sanders, Joseph E Schwartz, Amil Shah, Sanjiv J Shah, Lewis Smith, Wendy White, Sachin Yende, Elizabeth C Oelsner
doi : 10.1093/eurheartj/ehac205
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2196–2208
The aim is to evaluate associations of lung function impairment with risk of incident heart failure (HF).
HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
Bradley A Maron, Marc Humbert
doi : 10.1093/eurheartj/ehac201
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2209–2211
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial
Scott D Solomon, Brian L Claggett, Zi Michael Miao, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Ramon Corbalan, Gerasimos Filippatos, Assen R Goudev, Viatcheslav Mareev, Pranas Serpytis, Thomas Suter, Mehmet B Yilmaz, Faiez Zannad, Stuart Kupfer, Stephen B Heitner, Fady I Malik, John R Teerlink
doi : 10.1093/eurheartj/ehac144
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2212–2220
In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence of atrial fibrillation or flutter (AFF) on the effectiveness of omecamtiv mecarbil.
A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?
Peter van der Meer, Michiel Rienstra, Dirk J van Veldhuisen
doi : 10.1093/eurheartj/ehac197
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2221–2223
Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction
Jasper Tromp, Wouter Ouwerkerk, Tiew-Hwa K Teng, John G F Cleland, Sahiddah Bamadhaj, Christiane E Angermann, Ulf Dahlstrom, Wan Ting Tay, Kenneth Dickstein, Georg Ertl, Mahmoud Hassanein, Sergio V Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Sean P Collins, Gerasimos Filippatos, Carolyn S P Lam
doi : 10.1093/eurheartj/ehac103
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2224–2234
Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying a large share of the burden. Treatment for HF with reduced ejection fraction (HFrEF) improves survival but is often underused. Economic factors might have an important effect on the use of medicines.
Hospitalization for heart failure: a window of opportunity
Rolf Wachter, Karl-Philipp Rommel Rolf Wachter, Karl-Philipp Rommel
doi : 10.1093/eurheartj/ehac021
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2235–2236
Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies
Maria Generosa Crespo-Leiro, Maria Rosa Costanzo, Finn Gustafsson, Kiran K Khush, Peter S Macdonald, Luciano Potena, Josef Stehlik, Andreas Zuckermann, Mandeep R Mehra
doi : 10.1093/eurheartj/ehac204
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2237–2246
Heart transplantation is advocated in selected patients with advanced heart failure in the absence of contraindications.
Mixing the fat with water: are normal natriuretic peptide heart failure with preserved ejection fraction patients just more obese?
Aleix Olivella, Ana Belén Méndez, Ignacio Ferreira-González
doi : 10.1093/eurheartj/ehac192
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Page 2247
Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem
Frederik H Verbrugge, Barry A Borlaug
doi : 10.1093/eurheartj/ehac194
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Pages 2248–2249
Paradoxical enlargement of immunoglobulin G4 (IgG4)-related coronary aneurysms despite controlling serum IgG4 level
Yuhei Takei, Nobuya Abe, Miyuki Bohgaki, Hideki Kasahara
doi : 10.1093/eurheartj/ehac045
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Page 2250
Infectious endarteritis associated with patent ductus arteriosus and vegetation: a challenging diagnosis and treatment
Leizhi Ku, Youping Cheng, Xiaojing Ma
doi : 10.1093/eurheartj/ehac217
European Heart Journal, Volume 43, Issue 23, 14 June 2022, Page 2251
